Literature DB >> 27467134

Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact.

Brandon J Manley1, Abraham Ari Hakimi.   

Abstract

PURPOSE OF REVIEW: The daunting task of identifying key molecular drivers of renal cell carcinoma (RCC) has begun to reveal significant insights into tumor biology. This review provides an update on recent discoveries in this field and their possible clinical implications. RECENT
FINDINGS: Molecular profiles within the classic RCC histologic subtypes present distinctive appreciation of tumor biology and also allow for exploitation of targeted treatment regimens for patients with metastatic disease. Prognostic signatures have demonstrated the ability to accurately predict many clinical outcomes.
SUMMARY: The molecular and genomic profiling of RCC subtypes has identified a unique and diverse spectrum of alterations. Utilization of these characteristics to improve our prognostic and therapeutic outcomes in the clinical realm remains in its infancy but is rapidly advancing.

Entities:  

Mesh：

Year:  2016        PMID： 27467134      PMCID： PMC5032025          DOI： 10.1097/MOU.0000000000000307

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN： 0963-0643            Impact factor:   2.309


  64 in total

1.  The somatic genomic landscape of chromophobe renal cell carcinoma.

Authors:  Caleb F Davis; Christopher J Ricketts; Min Wang; Lixing Yang; Andrew D Cherniack; Hui Shen; Christian Buhay; Hyojin Kang; Sang Cheol Kim; Catherine C Fahey; Kathryn E Hacker; Gyan Bhanot; Dmitry A Gordenin; Andy Chu; Preethi H Gunaratne; Michael Biehl; Sahil Seth; Benny A Kaipparettu; Christopher A Bristow; Lawrence A Donehower; Eric M Wallen; Angela B Smith; Satish K Tickoo; Pheroze Tamboli; Victor Reuter; Laura S Schmidt; James J Hsieh; Toni K Choueiri; A Ari Hakimi; Lynda Chin; Matthew Meyerson; Raju Kucherlapati; Woong-Yang Park; A Gordon Robertson; Peter W Laird; Elizabeth P Henske; David J Kwiatkowski; Peter J Park; Margaret Morgan; Brian Shuch; Donna Muzny; David A Wheeler; W Marston Linehan; Richard A Gibbs; W Kimryn Rathmell; Chad J Creighton
Journal:  Cancer Cell       Date:  2014-08-21       Impact factor: 31.743

2.  Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma.

Authors:  A D Perera; E V Kleymenova; C L Walker
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

3.  Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.

Authors:  Richard W Joseph; Payal Kapur; Daniel J Serie; Jeanette E Eckel-Passow; Mansi Parasramka; Thai Ho; John C Cheville; Eugene Frenkel; Dinesh Rakheja; James Brugarolas; Alexander Parker
Journal:  Cancer       Date:  2013-12-30       Impact factor: 6.860

4.  Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution.

Authors:  Christopher G Przybycin; Angel M Cronin; Farbod Darvishian; Anuradha Gopalan; Hikmat A Al-Ahmadie; Samson W Fine; Ying-bei Chen; Melanie Bernstein; Paul Russo; Victor E Reuter; Satish K Tickoo
Journal:  Am J Surg Pathol       Date:  2011-07       Impact factor: 6.394

5.  Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases.

Authors:  M de Peralta-Venturina; H Moch; M Amin; P Tamboli; S Hailemariam; M Mihatsch; J Javidan; H Stricker; J Y Ro; M B Amin
Journal:  Am J Surg Pathol       Date:  2001-03       Impact factor: 6.394

6.  BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma.

Authors:  Payal Kapur; Alana Christie; Jay D Raman; Matthew T Then; Philipp Nuhn; Alexander Buchner; Patrick Bastian; Christian Seitz; Shahrokh F Shariat; Karim Bensalah; Nathalie Rioux-Leclercq; Xian-Jin Xie; Yair Lotan; Vitaly Margulis; James Brugarolas
Journal:  J Urol       Date:  2013-09-25       Impact factor: 7.450

7.  Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.

Authors:  Young Shin Song; Jung Ah Lim; Hoonsung Choi; Jae-Kyung Won; Jae Hoon Moon; Sun Wook Cho; Kyu Eun Lee; Young Joo Park; Ka Hee Yi; Do Joon Park; Jeong-Sun Seo
Journal:  Cancer       Date:  2016-03-11       Impact factor: 6.860

8.  Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.

Authors:  A Ari Hakimi; Ying-Bei Chen; James Wren; Mithat Gonen; Omar Abdel-Wahab; Adriana Heguy; Han Liu; Shugaku Takeda; Satish K Tickoo; Victor E Reuter; Martin H Voss; Robert J Motzer; Jonathan A Coleman; Emily H Cheng; Paul Russo; James J Hsieh
Journal:  Eur Urol       Date:  2012-09-27       Impact factor: 20.096

9.  Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.

Authors:  Payal Kapur; Samuel Peña-Llopis; Alana Christie; Leah Zhrebker; Andrea Pavía-Jiménez; W Kimryn Rathmell; Xian-Jin Xie; James Brugarolas
Journal:  Lancet Oncol       Date:  2013-01-16       Impact factor: 41.316

10.  Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3.

Authors:  Mark P Purdue; Mattias Johansson; Diana Zelenika; Jorge R Toro; Ghislaine Scelo; Lee E Moore; Egor Prokhortchouk; Xifeng Wu; Lambertus A Kiemeney; Valerie Gaborieau; Kevin B Jacobs; Wong-Ho Chow; David Zaridze; Vsevolod Matveev; Jan Lubinski; Joanna Trubicka; Neonila Szeszenia-Dabrowska; Jolanta Lissowska; Péter Rudnai; Eleonora Fabianova; Alexandru Bucur; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Paolo Boffetta; Joanne S Colt; Faith G Davis; Kendra L Schwartz; Rosamonde E Banks; Peter J Selby; Patricia Harnden; Christine D Berg; Ann W Hsing; Robert L Grubb; Heiner Boeing; Paolo Vineis; Françoise Clavel-Chapelon; Domenico Palli; Rosario Tumino; Vittorio Krogh; Salvatore Panico; Eric J Duell; José Ramón Quirós; Maria-José Sanchez; Carmen Navarro; Eva Ardanaz; Miren Dorronsoro; Kay-Tee Khaw; Naomi E Allen; H Bas Bueno-de-Mesquita; Petra H M Peeters; Dimitrios Trichopoulos; Jakob Linseisen; Börje Ljungberg; Kim Overvad; Anne Tjønneland; Isabelle Romieu; Elio Riboli; Anush Mukeria; Oxana Shangina; Victoria L Stevens; Michael J Thun; W Ryan Diver; Susan M Gapstur; Paul D Pharoah; Douglas F Easton; Demetrius Albanes; Stephanie J Weinstein; Jarmo Virtamo; Lars Vatten; Kristian Hveem; Inger Njølstad; Grethe S Tell; Camilla Stoltenberg; Rajiv Kumar; Kvetoslava Koppova; Olivier Cussenot; Simone Benhamou; Egbert Oosterwijk; Sita H Vermeulen; Katja K H Aben; Saskia L van der Marel; Yuanqing Ye; Christopher G Wood; Xia Pu; Alexander M Mazur; Eugenia S Boulygina; Nikolai N Chekanov; Mario Foglio; Doris Lechner; Ivo Gut; Simon Heath; Hélène Blanche; Amy Hutchinson; Gilles Thomas; Zhaoming Wang; Meredith Yeager; Joseph F Fraumeni; Konstantin G Skryabin; James D McKay; Nathaniel Rothman; Stephen J Chanock; Mark Lathrop; Paul Brennan
Journal:  Nat Genet       Date:  2010-12-05       Impact factor: 38.330
View more
  7 in total

1.  ARID1A knockdown triggers epithelial-mesenchymal transition and carcinogenesis features of renal cells: role in renal cell carcinoma.

Authors:  Keerakarn Somsuan; Paleerath Peerapen; Wanida Boonmark; Sirikanya Plumworasawat; Ratirath Samol; Natthiya Sakulsak; Visith Thongboonkerd
Journal:  FASEB J       Date:  2019-08-21       Impact factor: 5.191

2.  Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.

Authors:  Jad Chahoud; Pavlos Msaouel; Matthew T Campbell; Tharakeswara Bathala; Lianchun Xiao; Jianjun Gao; Amado J Zurita; Amishi Yogesh Shah; Eric Jonasch; Padmanee Sharma; Nizar M Tannir
Journal:  Oncologist       Date:  2019-09-09

3.  Coffee intake and trace element blood concentrations in association with renal cell cancer among smokers.

Authors:  Hongke Wu; Stephanie Weinstein; Lee E Moore; Demetrius Albanes; Robin Taylor Wilson
Journal:  Cancer Causes Control       Date:  2021-10-15       Impact factor: 2.506

4.  Molecular Characterization and Putative Pathogenic Pathways of Tuberous Sclerosis Complex-Associated Renal Cell Carcinoma.

Authors:  Jeong Hwan Park; Cheol Lee; Mee Soo Chang; Kwangsoo Kim; Seongmin Choi; Hyunjung Lee; Hyun-Seob Lee; Kyung Chul Moon
Journal:  Transl Oncol       Date:  2018-06-18       Impact factor: 4.243

5.  DNA methylation-based classification and identification of renal cell carcinoma prognosis-subgroups.

Authors:  Wenbiao Chen; Jia Zhuang; Peizhong Peter Wang; Jingjing Jiang; Chenhong Lin; Ping Zeng; Yan Liang; Xujun Zhang; Yong Dai; Hongyan Diao
Journal:  Cancer Cell Int       Date:  2019-07-16       Impact factor: 5.722

Review 6.  Novel emerging biomarkers to immunotherapy in kidney cancer.

Authors:  Yasser Ged; Martin H Voss
Journal:  Ther Adv Med Oncol       Date:  2021-11-25       Impact factor: 8.168

Review 7.  Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers.

Authors:  Filipa Amaro; Márcia Carvalho; Maria de Lourdes Bastos; Paula Guedes de Pinho; Joana Pinto
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.